Recent Comments
- M on The problem of erroneous diagnoses never falling off the chart
- Denis Donovan, MD on Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital.
- admin on Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital.
- Denis Donovan, MD on Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital.
- William Boden, MD on The ISCHEMIA trial PI, Judith Hochman, makes egregiously unfounded statements on national TV
Most Viewed Posts
- The Healthcare Channel hits 10 (4,676)
- How the FDA regulates compounding pharmacies (4,067)
- The new CDC guidelines for prescribing opioid pain pills (3,240)
- Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital. (2,830)
- The Who’s Teen Cancer Lounge at Sloan Kettering opens (2,693)
Pages
Categories
- – Biotech
- – Generics
- – JAMA
- – Medical Devices
- – NEJM
- – Opinion
- – Pharma
- – Policy
- – Reviews, books, devices
- – The Weekly Summary
- Bariatric surgery
- Cardiac surgery
- Cardiology
- Dermatology
- Diabetes and endocrinology
- Emergency medicine
- Gastroenterology and liver
- General surgery
- Genetics
- Geriatrics
- Infectious disease
- Internal Medicine
- Neurology
- Neurosurgery
- Obstetrics and Gynecology
- Oncology
- Ophthalmology
- Orthopedic surgery
- Pediatrics
- Plastic surgery
- Primary care medicine
- Psychology Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Spine surgery
- Sports medicine
- Transplant surgery
- Trauma Surgery
- Uncategorized
- Urology
- Vascular Surgery
- Z Medical centers
- Baylor
- Boston University
- Cedars Sinai
- Cleveland Clinic
- Columbia
- Cornell
- Duke
- Emory
- George Washington Univ
- Harvard
- Henry Ford
- Iowa State
- Johns Hopkins
- Mayo Clinic
- McMaster University
- Medical University of South Carolina
- Memorial Sloan-Kettering
- Michigan
- National Jewish Health
- NYU
- Ohio State
- Oregon Health and Science University
- UC Davis
- UC San Francisco
- UCLA
- Univ Kentucky
- Univ Maryland
- Univ Miami
- Univ Michigan
- Univ of Louisville
- Univ Texas
- VA Walter Reed
- Vanderbilt
- VCU
- Washington University
- Yale
Category Archives: – Biotech
CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?
September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Interview with the CEO of Synthetic Biologics, Jeff Riley
February 8, 2016- Interviewed by Steven E. Greer, MD
The Biggest Healthcare Stories of 2016
December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug
Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA
Leave a comment
Ibrance (palbociclib) to treat advanced breast cancer
November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,
The Biggest stories of 2015
December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,
The telomerase inhibitor Imetelstat developed by Geron
September 9, 2015-
Posted in - Biotech, - NEJM, Oncology
Leave a comment
Are the new PCSK9 cholesterol lowering drugs worth the high cost?
December 16, 2015- Interviewed by Steven E. Greer, MD
Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA
Leave a comment
Martin Shkreli, CEO of Turing Pharmaceuticals, could be the Bernie Madoff of the drug industry
September 22, 2015- by Steven E. Greer, MD Making national news today was Martin Shkreli, the baby-faced, greasy-haired, disheveled-looking
Posted in - Biotech, - Pharma, Congress, FDA
Leave a comment
Actavis 1000% drug price hike: a case for healthcare reform
Update September 21, 2015- The Healthcare Channel was the first to report in 2009 on the business strategy of acquiring cheap generic drugs, cornering the market, then raising
Posted in - Biotech, - Generics, - Opinion, - Policy, CMS, Congress, FDA, Infectious disease
Leave a comment
The PCSK9 LDL drugs do not cut heart risk in half
March 18, 2015- Op-Ed by Steven E. Greer, MD The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data
New therapies for hepatitis C
November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care
Super rapid acting insulin and inhaled insulin
September 9, 2013- Interviewed by Steven E. Greer, MD Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University
Posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami
Leave a comment
anti-PD1 and anti-PD-L1 drugs treating NSCLC
March 26, 2013 Interviewed By Steven E. Greer, MD
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
The Damon Runyon Cancer Research Foundation panel
March 8, 2013 By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon
Posted in - Biotech, - Pharma, Harvard, Oncology
Leave a comment
Paul Richardson, MD: Three-drug regimen for multiple myeloma
December 15, 2015 Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article
Posted in - Biotech, - Pharma, Harvard, Oncology
Leave a comment
Steven Cummings, MD: The denosumab FREEDOM trial
August 11, 2009- Dr. Steven Cummings, director of the San Francisco Coordinating Center and faculty of UCSF, and
Sundeep Khosla, MD discusses Amgen’s Denosumab
August 11, 2009- Sundeep Khosla of the Mayo Clinic who authored the NEJM editorial on Amgen’s denosumab
Posted in - Biotech, - Pharma, Mayo Clinic
Leave a comment